Profusa (NVACW) Debt to Equity (2021 - 2026)

Profusa posted quarterly Debt to Equity of -$0.25 for Q1 2026, down 14.1% year-on-year from -$0.29 in Q1 2025, and down 15701.46% on a QoQ basis from -$0.0 in Q4 2025.

Profusa (NVACW) has 5 years of Debt to Equity data on file, last reported at -$0.25 in Q1 2026.

  • For the quarter ending Q1 2026, Debt to Equity fell 14.1% year-over-year to -$0.25; the trailing twelve-month figure through Mar 2026 stood at -$0.25 (down 14.1% YoY), and the FY2025 full-year result was -$0.0, up 99.59% from the prior year.
  • Debt to Equity for Q1 2026 stood at -$0.25, down from -$0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.0 in Q4 2025 and bottomed at -$0.39 in Q4 2024.
  • The 4-year median for Debt to Equity is -$0.08 (2025), against an average of -$0.13.
  • The widest annual swing landed in 2022, when Debt to Equity sank 14684.68%; it then jumped 99.59% in 2025.
  • A 4-year view of Debt to Equity shows it stood at -$0.04 in 2022, then slumped by 854.56% to -$0.39 in 2024, then surged by 99.59% to -$0.0 in 2025, then slumped by 15701.46% to -$0.25 in 2026.
  • The last three Debt to Equity figures came in at -$0.25 (Q1 2026), -$0.0 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.65
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.64
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.57
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.95
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 0.27
10 Profusa - - - -0.25

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.25
Dec 31, 2025 -0.16
Sep 30, 2025 -0.13
Dec 31, 2024 -0.39
Dec 31, 2022 -0.04
Sep 30, 2022 -0.03
Jun 30, 2022 0.00
Dec 31, 2021 0.00